• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

    3/25/25 4:05:00 PM ET
    $TSVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TSVT alert in real time by email

    Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025

    Abecma generated $242 million U.S. sales in 2024

    79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure

    Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities

    2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024.

    "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma," said Chip Baird, chief executive officer, 2seventy bio. "This week marks four years since Abecma received FDA approval as the first anti-BCMA CAR T cell therapy approved for relapsed or refractory multiple myeloma. Together with BMS, we remain committed to expanding the reach of this important therapy. We launched 2seventy with the goal of providing more time to patients, and we believe with BMS' experience and resources, we can continue to improve outcomes for people living with multiple myeloma."

    On March 10, 2seventy bio announced a definitive merger agreement to be acquired by Bristol Myers Squibb (BMS). Under the terms of the agreement, BMS will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction. 2seventy bio's Board of Directors unanimously recommends that 2seventy bio stockholders tender their shares in the tender offer.

    ABECMA COMMERCIAL AND REGULATORY HIGHLIGHTS

    • Full year Abecma® (idecabtagene vicleucel; ide-cel) U.S. sales, as reported by Bristol Myers Squibb (BMS), were $242 million.
    • 2seventy bio and BMS continue to focus on competitively differentiating Abecma's safety and efficacy profile supported by the strength of the KarMMa-3 and real-world data.
    • The Company and BMS share equally in all profits and losses related to development, manufacturing, and commercialization of Abecma in the U.S. 2seventy bio reported share of collaboration loss of approximately $3.3 million related to the collaboration with BMS for the three months ended December 31, 2024.

    SELECT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

    • Total revenues were $2.9 million for the three months ended December 31, 2024, compared to $10.7 million for the three months ended December 31, 2023. Total revenues were $37.9 million for the twelve months ended December 31, 2024, compared to $100.4 million for the twelve months ended December 31, 2023.
    • Research and development expenses were $8.7 million for the three months ended December 31, 2024, compared to $51.2 million for the three months ended December 31, 2023. Research and development expenses were $76.9 million for the twelve months ended December 31, 2024, compared to $230.8 million for the twelve months ended December 31, 2023.
    • Selling, general and administrative expenses were $8.5 million for the three months ended December 31, 2024, compared to $16.2 million for the three months ended December 31, 2023. Selling, general and administrative expenses were $43.9 million for the twelve months ended December 31, 2024, compared to $69.4 million for the twelve months ended December 31, 2023.
    • Net loss was $19.5 million for the three months ended December 31, 2024, compared to $56.8 million for the three months ended December 31, 2023. Net loss was $57.2 million for the twelve months ended December 31, 2024, compared to $217.6 million for the twelve months ended December 31, 2023.
    • Cash, cash equivalents, and marketable securities totaled $183.6 million as of December 31, 2024.

    Merger Agreement Details and Path to Completion

    The closing of the transaction with BMS is expected to occur in the second quarter of 2025 and is subject to customary closing conditions, including the tender of a majority of the outstanding shares of 2seventy bio's common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following the successful closing of the tender offer, BMS will acquire all remaining shares of 2seventy bio common stock that are not tendered in the tender offer through a second-step merger at the same price in the tender offer of $5.00 per share.

    Following the completion of this transaction, 2seventy bio's common stock will no longer be listed for trading on Nasdaq.

    In connection with the execution of the merger agreement, certain stockholders of 2seventy bio owning approximately 5.3% of the outstanding shares of 2seventy bio's common stock have entered into tender and support agreements pursuant to which they have agreed to tender all of their owned shares in the offer.

    In light of the announced transaction, 2seventy will not be hosting an earnings conference call or providing financial guidance for 2025.

    ABECMA U.S. INDICATION

    ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

    U.S. Important Safety Information

    BOXED WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED CYTOPENIA and SECONDARY HEMATOLOGICAL MALIGNANCIES

    • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with ABECMA. Do not administer ABECMA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
    • Neurologic Toxicities, which may be severe or life-threatening, occurred following treatment with ABECMA, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with ABECMA. Provide supportive care and/or corticosteroids as needed.
    • Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with ABECMA. HLH/MAS can occur with CRS or neurologic toxicities.
    • Prolonged Cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment with ABECMA.
    • T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA
    • ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS.

    Warnings and Precautions:

    Early Death: In KarMMa-3, a randomized (2:1), controlled trial, a higher proportion of patients experienced death within 9 months after randomization in the ABECMA arm (45/254; 18%) compared to the standard regimens arm (15/132; 11%). Early deaths occurred in 8% (20/254) and 0% prior to ABECMA infusion and standard regimen administration, respectively, and 10% (25/254) and 11% (15/132) after ABECMA infusion and standard regimen administration, respectively. Out of the 20 deaths that occurred prior to ABECMA infusion, 15 occurred from disease progression, 3 occurred from adverse events and 2 occurred from unknown causes. Out of the 25 deaths that occurred after ABECMA infusion, 10 occurred from disease progression, 11 occurred from adverse events, and 4 occurred from unknown causes.

    Cytokine Release Syndrome (CRS): CRS, including fatal or life-threatening reactions, occurred following treatment with ABECMA. Among patients receiving ABECMA for relapsed refractory multiple myeloma in the KarMMa and KarMMa-3 studies (N=349), CRS occurred in 89% (310/349), including ≥ Grade 3 CRS (Lee grading system) in 7% (23/349) of patients and Grade 5 CRS in 0.9% (3/349) of patients. The median time-to-onset of CRS, any grade, was 1 day (range: 1 to 27 days), and the median duration of CRS was 5 days (range: 1 to 63 days). In the pooled studies, the rate of ≥Grade 3 CRS was 10% (7/71) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 5.4% (13/241) for patients treated in dose range of 300 to 460 x 106 CAR-positive T cells.

    The most common manifestations of CRS (greater than or equal to 10%) included pyrexia (87%), hypotension (30%), tachycardia (26%), chills (19%), hypoxia (16%). Grade 3 or higher events that may be associated with CRS include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, ARDS, atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, coagulopathy, renal failure, multiple organ dysfunction syndrome and HLH/MAS.

    Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS.

    Of the 349 patients who received ABECMA in clinical trials, 226 (65%) patients received tocilizumab; 39% (135/349) received a single dose, while 26% (91/349) received more than 1 dose of tocilizumab. Overall, 24% (82/349) of patients received at least 1 dose of corticosteroids for treatment of CRS. Almost all patients who received corticosteroids for CRS also received tocilizumab. For patients treated in dose range of 460 to 510 x 106 CAR-positive T cells, 76% (54/71) of patients received tocilizumab and 35% (25/71) received at least 1 dose of corticosteroids for treatment of CRS. For patients treated in dose range of 300 to 460 x 106 CAR-positive T cells, 63% (152/241) of patients received tocilizumab and 20% (49/241) received at least 1 dose of corticosteroid for treatment of CRS.

    Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms of CRS and monitor patients for signs or symptoms of CRS for at least 4 weeks after ABECMA infusion. At the first sign of CRS, institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated. Ensure that a minimum of 2 doses of tocilizumab are available prior to infusion of ABECMA. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time.

    Neurologic Toxicities: Neurologic toxicities, including immune-effector cell-associated neurotoxicity (ICANS), which may be severe or life- threatening, occurred concurrently with CRS, after CRS resolution, or in the absence of CRS following treatment with ABECMA.

    In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, CAR T cell-associated neurotoxicity occurred in 40% (139/349), including Grade 3 in 4% (14/349) and Grade 4 in 0.6% (2/349) of patients. The median time to onset of neurotoxicity was 2 days (range: 1 to 148 days). The median duration of CAR T cell-associated neurotoxicity was 8 days (range: 1 to 720 days) in all patients including those with ongoing neurologic events at the time of death or data cut off. CAR T cell-associated neurotoxicity resolved in 123 of 139 (88%) patients and median time to resolution was 5 days (range: 1 to 245 days). One-hundred and thirty four out of 349 (38%) patients with neurotoxicity had CRS. The onset of neurotoxicity during CRS was observed in 93 patients, before the onset of CRS in 12 patients, and after the CRS event in 29 patients. The rate of Grade 3 or 4 CAR T cell-associated neurotoxicity was 5.6% (4/71) and 3.7% (9/241) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 300 to 460 x 106 CAR-positive T cells, respectively. The most frequent (greater than or equal to 5%) manifestations of CAR T cell-associated neurotoxicity include encephalopathy (21%), headache (15%), dizziness (8%), delirium (6%), and tremor (6%).

    At the safety update for KarMMa-3 study, one patient developed fatal neurotoxicity 43 days after ABECMA. In KarMMa, one patient had ongoing Grade 2 neurotoxicity at the time of death. Two patients had ongoing Grade 1 tremor at the time of data cutoff.

    Cerebral edema has been associated with ABECMA in a patient in another study in multiple myeloma. Grade 3 myelitis and Grade 3 parkinsonism have occurred after treatment with ABECMA in another study in multiple myeloma.

    Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms of neurologic toxicities and monitor patients for signs or symptoms of neurologic toxicities for at least 4 weeks after ABECMA infusion and treat promptly. Rule out other causes of neurologic symptoms. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed. Counsel patients to seek immediate medical attention should signs or symptoms occur at any time.

    Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, HLH/MAS occurred in 2.9% (10/349) of patients. All events of HLH/MAS had onset within 10 days of receiving ABECMA, with a median onset of 6.5 days (range: 4 to 10 days) and occurred in the setting of ongoing or worsening CRS. Five patients with HLH/MAS had overlapping neurotoxicity. The manifestations of HLH/MAS include hypotension, hypoxia, multiple organ dysfunction, renal dysfunction and cytopenia.

    In KarMMa-3, one patient had Grade 5, two patients had Grade 4 and two patients had Grade 3 HLH/MAS. The patient with Grade 5 HLH/MAS also had Grade 5 candida sepsis and Grade 5 CRS. In another patient who died due to stroke, the Grade 4 HLH/MAS had resolved prior to death. Two cases of Grade 3 and one case of Grade 4 HLH/MAS had resolved.

    In KarMMa, one patient treated in the 300 x 106 CAR-positive T cells dose cohort developed fatal multi-organ HLH/MAS with CRS. In another patient with fatal bronchopulmonary aspergillosis, HLH/MAS was contributory to the fatal outcome. Three cases of Grade 2 HLH/MAS resolved.

    HLH/MAS is a potentially life-threatening condition with a high mortality rate if not recognized early and treated. Treatment of HLH/MAS should be administered per institutional guidelines.

    ABECMA REMS: Due to the risk of CRS and neurologic toxicities, ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS. Further information is available at www.AbecmaREMS.com or contact Bristol-Myers Squibb at 1-866-340-7332.

    Hypersensitivity Reactions: Allergic reactions may occur with the infusion of ABECMA. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) in ABECMA.

    Infections: ABECMA should not be administered to patients with active infections or inflammatory disorders. Severe, life-threatening, or fatal infections occurred in patients after ABECMA infusion.

    In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, infections (all grades) occurred in 61% of patients. Grade 3 or 4 infections occurred in 21% of patients. Grade 3 or 4 infections with an unspecified pathogen occurred in 12%, viral infections in 7%, bacterial infections in 4.3%, and fungal infections in 1.4% of patients. Overall, 15 patients had Grade 5 infections (4.3%); 8 patients (2.3%) with infections of pathogen unspecified, 3 patients (0.9%) with fungal infections, 3 patients (0.9%) with viral infections, and 1 patient (0.3%) with bacterial infection.

    Monitor patients for signs and symptoms of infection before and after ABECMA infusion and treat appropriately. Administer prophylactic, pre-emptive, and/or therapeutic antimicrobials according to standard institutional guidelines.

    Febrile neutropenia was observed in 38% (133/349) of patients after ABECMA infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

    Viral Reactivation: Cytomegalovirus (CMV) infection resulting in pneumonia and death has occurred following ABECMA administration. Monitor and treat for CMV reactivation in accordance with clinical guidelines. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against plasma cells. Perform screening for CMV, HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice.

    Prolonged Cytopenias: In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, 40% of patients (139/349) experienced prolonged Grade 3 or 4 neutropenia and 42% (145/349) experienced prolonged Grade 3 or 4 thrombocytopenia that had not resolved by Month 1 following ABECMA infusion. In 89% (123/139) of patients who recovered from Grade 3 or 4 neutropenia after Month 1, the median time to recovery from ABECMA infusion was 1.9 months. In 76% (110/145) of patients who recovered from Grade 3 or 4 thrombocytopenia, the median time to recovery was 1.9 months. Five patients underwent stem cell therapy for hematopoietic reconstitution due to prolonged cytopenia. The rate of Grade 3 or 4 thrombocytopenia was 62% (44/71) and 56% (135/241) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 300 to 460 x 106 CAR-positive T cells, respectively.

    Monitor blood counts prior to and after ABECMA infusion. Manage cytopenia with myeloid growth factor and blood product transfusion support according to local institutional guidelines.

    Hypogammaglobulinemia: In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, hypogammaglobulinemia was reported as an adverse event in 13% (46/349) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 37% (130/349) of patients treated with ABECMA.

    Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion occurred in 45% (158/349) of patients treated with ABECMA. Forty-one percent of patients received intravenous immunoglobulin (IVIG) post-ABECMA for serum IgG <400 mg/dL.

    Monitor immunoglobulin levels after treatment with ABECMA and administer IVIG for IgG <400 mg/dl. Manage appropriately per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis.

    Use of Live Vaccines: The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA.

    Secondary Malignancies: Patients treated with ABECMA may develop secondary malignancies. In KarMMa-3, myeloid neoplasms (four cases of myelodysplastic syndrome and one case of acute myeloid leukemia) occurred in 2.2% (5/222) of patients following treatment with ABECMA compared to none in the standard regimens arm at the time of the safety update. The median time to onset of myeloid neoplasm from ide-cel infusion was 338 days (Range: 277 to 794 days). Three of these five patients have died following the development of myeloid neoplasm. One out of the five cases of myeloid neoplasm occurred after initiation of subsequent antimyeloma therapy.

    T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes.

    Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1‑888‑805‑4555 for reporting and to obtain instructions on collection of patient samples for testing of secondary malignancy.

    Effects on Ability to Drive and Operate Machinery: Due to the potential for neurologic events, including altered mental status or seizures, patients receiving ABECMA are at risk for altered or decreased consciousness or coordination in the 8 weeks following ABECMA infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.

    Adverse Reactions: The most common nonlaboratory adverse reactions (incidence greater than or equal to 20%) include pyrexia, CRS, hypogammaglobulinemia, infections – pathogen unspecified, musculoskeletal pain, fatigue, febrile neutropenia, hypotension, tachycardia, diarrhea, nausea, headache, chills, upper respiratory tract infection, encephalopathy, edema, dyspnea and viral infections.

    Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide.

    About Bristol Myers Squibb and 2seventy bio

    Abecma is being jointly developed and commercialized in the U.S. as part of a Co-Development, Co-Promotion, and Profit Share Agreement between Bristol Myers Squibb and 2seventy bio. Bristol Myers Squibb assumes sole responsibility for Abecma drug product manufacturing and commercialization outside of the U.S. The companies' clinical development program for Abecma includes ongoing clinical studies (KarMMa-2, KarMMa-3) in earlier lines of treatment for patients with multiple myeloma. For more information visit clinicaltrials.gov.

    About 2seventy bio

    Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body's immune response to tumor cells and how to translate cell therapies into practice, we're applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our "why" and keeping our people and culture top of mind every day. For more information, visit www.2seventybio.com.

    Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

    2seventy bio is a trademark of 2seventy bio, Inc.

    Cautionary Note Regarding Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of applicable laws and regulations. These statements include but are not limited to: statements regarding the proposed acquisition of 2seventy bio, Inc. ("2seventy bio") by Bristol Myers Squibb ("BMS"), the expected timetable for completing the transaction, future opportunities for the combined businesses, the expected benefits of BMS's acquisition of 2seventy bio and the development and commercialization of Abecma. These statements may be identified by the fact they use words such as "should," "could," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "will" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them, that are difficult to predict, may be beyond 2seventy bio's control and could cause actual outcomes and results to differ materially from those expressed in, or implied by, the forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the timing of the tender offer and subsequent merger, (ii) the number of shares of 2seventy bio common stock that will be tendered in the tender offer, (iii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iv) the risk that legal proceedings may be instituted related to the merger agreement, (v) any competing offers or acquisition proposals for 2seventy bio, (vi) the possibility that various conditions to the consummation of the tender offer or the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the offer or the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed acquisition, including the response of business partners and competitors to the announcement of the proposed acquisition or difficulties in employee retention as a result of the announcement and pendency of the proposed acquisition. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect BMS's business and market, particularly those identified in the cautionary statement and risk factors discussion in BMS's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent Quarterly Reports on Form 10-Q, and 2seventy bio's business, particularly those identified in the risk factors discussion in 2seventy bio's Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent Quarterly Reports on Form 10-Q, as well as other documents that may be filed by BMS or 2seventy bio from time to time with the SEC. 2seventy bio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made and readers are cautioned not to place undue reliance on such statements.

    Additional Information and Where to Find It

    The tender offer described in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of 2seventy bio or any other securities, nor is it a substitute for the tender offer materials described herein. At the time the planned tender offer is commenced, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed by BMS ("BMS") and Daybreak Merger Sub Inc., a wholly owned indirect subsidiary of BMS, with the Securities and Exchange Commission ("SEC"), and a solicitation/recommendation statement on Schedule 14D-9 will be filed by 2seventy bio with the SEC. The offer to purchase shares of 2seventy bio common stock will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO.

    INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY READ BOTH THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND RELATED DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES.

    Investors and security holders may obtain a free copy of the offer to purchase, the related letter of transmittal, certain other tender offer documents and the solicitation/recommendation statement, when available, and other documents filed with the SEC on the SEC's website at www.sec.gov or by directing such requests to the information agent for the offer, which will be named in the tender offer statement. The offer to purchase and related tender offer documents may also be obtained for free on BMS' website at www.bms.com/investors or 2seventy bio's website at https://ir.2seventybio.com/. In addition, BMS and 2seventy bio each files annual, quarterly and current reports and other information with the SEC, which are also available to the public at no charge at www.sec.gov.

    2seventy bio, Inc.

    Consolidated Statements of Operations and Comprehensive Loss

    (unaudited)

    (in thousands, except per share data)

     

    For the three months ended

    December 31,

     

    For the twelve months ended

    December 31,

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Revenue:
    Service revenue

    $

    2,926

     

    $

    3,348

     

    $

    18,118

     

    $

    24,144

     

    Collaborative arrangement revenue

     

    -

     

     

    7,336

     

     

    19,744

     

     

    71,601

     

    Royalty and other revenue

     

    -

     

     

    -

     

     

    -

     

     

    4,642

     

    Total revenues

     

    2,926

     

     

    10,684

     

     

    37,862

     

     

    100,387

     

    Operating expenses:
    Research and development

     

    8,653

     

     

    51,217

     

     

    76,917

     

     

    230,758

     

    Cost of manufacturing for commercial collaboration

     

    5,520

     

     

    3,147

     

     

    18,010

     

     

    14,819

     

    Selling, general and administrative

     

    8,524

     

     

    16,201

     

     

    43,924

     

     

    69,414

     

    Share of collaboration loss

     

    3,323

     

     

    -

     

     

    4,553

     

     

    -

     

    Restructuring expenses

     

    171

     

     

    -

     

     

    12,303

     

     

    8,614

     

    Cost of royalty and other revenue

     

    -

     

     

    -

     

     

    -

     

     

    2,099

     

    Change in fair value of contingent consideration

     

    -

     

     

    55

     

     

    (2,415

    )

     

    235

     

    Goodwill impairment charge

     

    -

     

     

    -

     

     

    -

     

     

    12,056

     

    Total operating expenses

     

    26,191

     

     

    70,620

     

     

    153,292

     

     

    337,995

     

    Loss from operations

     

    (23,265

    )

     

    (59,936

    )

     

    (115,430

    )

     

    (237,608

    )

    Interest income, net

     

    2,632

     

     

    3,648

     

     

    10,875

     

     

    12,413

     

    Other income (expense), net

     

    1,114

     

     

    (534

    )

     

    4,347

     

     

    7,625

     

    Gain on sale of assets to Novo Nordisk

     

    -

     

     

    -

     

     

    47,987

     

     

    -

     

    Loss on assets held for sale to Regeneron

     

    -

     

     

    -

     

     

    (5,026

    )

     

    -

     

    Loss before income taxes

     

    (19,519

    )

     

    (56,822

    )

     

    (57,247

    )

     

    (217,570

    )

    Income tax (expense) benefit

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    Net loss

    $

    (19,519

    )

    $

    (56,822

    )

    $

    (57,247

    )

    $

    (217,570

    )

    Net loss per share - basic and diluted

    $

    (0.37

    )

    $

    (1.11

    )

    $

    (1.10

    )

    $

    (4.42

    )

    Weighted-average number of common shares used in computing net loss per share - basic and diluted

     

    52,344

     

     

    51,383

     

     

    52,218

     

     

    49,276

     

    2seventy bio, Inc.

    Consolidated Balance Sheet Data

    (unaudited)

    (in thousands)

     

     

     

    As of December 31,

    2024

     

    As of December 31,

    2023

    Cash, cash equivalents and marketable securities

    $

    183,621

    $

    221,805

    Total assets

     

    479,510

     

    565,426

    Total liabilities

     

    268,704

     

    310,126

    Total stockholders' equity

     

    210,806

     

    255,300

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250325781698/en/

    Investors and Media:

    Vicki Eatwell, CFO

    [email protected]

    Morgan (Adams) Shields

    [email protected]

    Get the next $TSVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSVT

    DatePrice TargetRatingAnalyst
    6/6/2024$5.00 → $2.00Neutral → Sell
    Goldman
    1/31/2024Outperform → Market Perform
    TD Cowen
    1/31/2024$5.00 → $18.00Market Perform → Outperform
    Leerink Partners
    10/30/2023$6.00Outperform → Market Perform
    Leerink Partners
    10/12/2023$13.00Buy
    Citigroup
    9/13/2023$5.00Buy → Neutral
    Goldman
    9/12/2023Buy → Neutral
    Guggenheim
    7/28/2023$25.00 → $13.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TSVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Snow Jessica sold $11,364 worth of shares (2,298 units at $4.95), decreasing direct ownership by 0.90% to 254,193 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:49:01 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Baird William D Iii sold $25,180 worth of shares (5,092 units at $4.95), decreasing direct ownership by 0.45% to 1,121,034 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:48:27 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Eatwell Victoria sold $12,817 worth of shares (2,592 units at $4.95), decreasing direct ownership by 0.58% to 444,387 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:48:17 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 2seventy bio downgraded by Goldman with a new price target

      Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously

      6/6/24 7:21:43 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio downgraded by TD Cowen

      TD Cowen downgraded 2seventy bio from Outperform to Market Perform

      1/31/24 9:14:22 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously

      1/31/24 7:24:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

      Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

      5/7/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

      Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

      3/25/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

      $5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions 2seventy bio, Inc. (NASDAQ:TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE:BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. "A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living wi

      3/10/25 10:17:00 PM ET
      $BMY
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 2seventy bio Inc.

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      11/6/24 4:06:39 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 2seventy bio Inc. (Amendment)

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      2/14/24 4:58:16 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 2seventy bio Inc. (Amendment)

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      2/14/24 4:21:54 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Capital, Llc bought $203,992 worth of shares (40,000 units at $5.10) (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/28/24 8:29:09 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Casdin Capital, Llc bought $3,899,050 worth of shares (777,377 units at $5.02) (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/25/24 9:44:59 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    SEC Filings

    See more
    • SEC Form 10-Q filed by 2seventy bio Inc.

      10-Q - 2seventy bio, Inc. (0001860782) (Filer)

      5/7/25 4:16:20 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - 2seventy bio, Inc. (0001860782) (Filer)

      5/7/25 4:12:38 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.

      SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)

      5/6/25 7:57:30 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Financials

    Live finance-specific insights

    See more
    • 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

      Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

      5/7/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

      Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

      3/25/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

      Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for

      11/12/24 7:00:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Leadership Updates

    Live Leadership Updates

    See more
    • 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

      2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan

      3/20/24 5:04:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

      Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

      12/6/23 8:00:00 AM ET
      $BLUE
      $TSVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Deep Genomics Announces the Appointment of Brian O'Callaghan as CEO

      O'Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume new role of chief innovation officer, remain a member of the board and bolster plans for further technology development and innovation, leveraging artificial intelligence (AI) to decode RNA biology for novel drug development Lead independent director Chip Baird appointed as chair of the board Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines

      9/15/23 7:00:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care